2',4'-二氟-4-羟基[1,1'-联苯]-3-羧酸钠 | 84145-00-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2',4'-二氟-4-羟基[1,1'-联苯]-3-羧酸钠
• CAS: 84145-00-6
• 化学式: C13H8F2NaO3
• 分子量: 273.19
• InChiKey: CGZRRHAQFABLPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.65
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Improved anti-inflammatory combinations having reduced ulcerogenicity
  申请人：Merck & Co., Inc.

  公开号：EP0017169A1

  公开（公告）日：1980-10-15

  A novel drug combination for more effective treatment of pain, fever, and inflammation with reduced ulcerogenicity comprising either 1-(p-chlorobenzoyl)-5-methoxy-2-methylindo|e-3-acetic acid (indomethacin), and (b) a member selected from phenyl benzoic acid compounds, especially 2-hydroxy-5-(2',4'-difluorophenyl)benzoic acid (diflunisal), wherein the molar ratio of (b) to (a) is from 0.5 to 1.0 to 15.0 to 1.0; or a member selected from (b) and one or more members selected from ibuprofen, ketoprofen, naproxen, diclofenac sodium, tolmetin, flurbiprofen, indoprofen, benozaprofen, piroxicam.

  一种用于更有效地治疗疼痛、发热和炎症并降低溃疡发生率的新型药物组合，包括 1-(对氯苯甲酰基)-5-甲氧基-2-甲基吲哚|e-3-乙酸(吲哚美辛)，和(b)选自苯基苯甲酸化合物，特别是 2-羟基-5-(2',4'-二氟苯基)苯甲酸(二氟尼柳)的成员，其中(b)与(a)的摩尔比为 0.5至1.0至15.0至1.0；或选自(b)和一种或多种选自布洛芬、酮洛芬、萘普生、双氯芬酸钠、托美汀、氟比洛芬、吲哚洛芬、苯唑洛芬、吡罗昔康的成员。
• Composition containing a phenyl benzoic acid compound and acetaminophen combination for the treatment of pain and inflammation and process for preparing the same
  申请人：Merck & Co., Inc.

  公开号：EP0017102A1

  公开（公告）日：1980-10-15

  A drug combination for more effective treatment of pain and inflammation comprising (a) a halogenated phenyl benzoic acid compound and (b) acetaminophen. The combination exhibits more rapid onset of action and more extended action, and provides more safety and fewer side effects than either ingredient alone.

  一种能更有效治疗疼痛和炎症的复方药物，由(a)卤代苯基苯甲酸化合物和(b)对乙酰氨基酚组成。与单独使用其中一种成分相比，这种复方制剂起效更快，作用时间更长，安全性更高，副作用更少。
• NON-INCLUSION CYCLODEXTRIN COMPLEXES
  申请人：Decode Genetics EHF

  公开号：EP1443969A2

  公开（公告）日：2004-08-11
• Non-inclusion cyclodextrin complexes
  申请人：——

  公开号：US20030109492A1

  公开（公告）日：2003-06-12

  The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with &bgr;-cyclodextrin in an aqueous complexation medium comprising &bgr;-cyclodextrin and a negatively- or positively-charged compound which forms an inclusion or non-inclusion complex with &bgr;-cyclodextrin and its inclusion complexes.
• Conveniently implantable sustained release drug compositions
  申请人：Wong G. Vernon

  公开号：US20080038316A1

  公开（公告）日：2008-02-14

  This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.